MKKGY Quote, Financials, Valuation and Earnings

BioNTech SE has a net margin of 13.92% compared to Merck KGaA's net margin of -227.46%. Merck KGaA's return on equity of 9.69% beat BioNTech SE's return on equity of -3.91%.

Merck KGaA has a consensus price target of $35.10, signalling upside risk potential of 36.15%. On the other hand BioNTech SE has an analysts' consensus of $136.68 which suggests that it could grow by 23.14%. Given that Merck KGaA has higher upside potential than BioNTech SE, analysts believe Merck KGaA is more attractive than BioNTech SE.

Merck KGaA has a beta of 0.941, which suggesting that the stock is 5.883% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.283, suggesting its more volatile than the S&P 500 by 28.318%.

Merck KGaA has a quarterly dividend of $0.50 per share corresponding to a yield of 1.94%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck KGaA pays 10.23% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Merck KGaA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck KGaA quarterly revenues are $5.6B, which are larger than BioNTech SE quarterly revenues of $192.3M. Merck KGaA's net income of $773.4M is higher than BioNTech SE's net income of -$437.5M. Notably, Merck KGaA's price-to-earnings ratio is 18.49x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.45x versus 9.00x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

CureVac NV has a net margin of 13.92% compared to Merck KGaA's net margin of -5832.47%. Merck KGaA's return on equity of 9.69% beat CureVac NV's return on equity of 32.68%.

Merck KGaA has a consensus price target of $35.10, signalling upside risk potential of 36.15%. On the other hand CureVac NV has an analysts' consensus of $4.80 which suggests that it could fall by -12.05%. Given that Merck KGaA has higher upside potential than CureVac NV, analysts believe Merck KGaA is more attractive than CureVac NV.

Merck KGaA has a beta of 0.941, which suggesting that the stock is 5.883% less volatile than S&P 500. In comparison CureVac NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Merck KGaA has a quarterly dividend of $0.50 per share corresponding to a yield of 1.94%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck KGaA pays 10.23% of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend. Merck KGaA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck KGaA quarterly revenues are $5.6B, which are larger than CureVac NV quarterly revenues of $939.6K. Merck KGaA's net income of $773.4M is higher than CureVac NV's net income of -$54.8M. Notably, Merck KGaA's price-to-earnings ratio is 18.49x while CureVac NV's PE ratio is 6.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.45x versus 2.14x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.

InflaRx NV has a net margin of 13.92% compared to Merck KGaA's net margin of -14092.9%. Merck KGaA's return on equity of 9.69% beat InflaRx NV's return on equity of -56.78%.

Merck KGaA has a consensus price target of $35.10, signalling upside risk potential of 36.15%. On the other hand InflaRx NV has an analysts' consensus of $3.62 which suggests that it could grow by 305.61%. Given that InflaRx NV has higher upside potential than Merck KGaA, analysts believe InflaRx NV is more attractive than Merck KGaA.

Merck KGaA has a beta of 0.941, which suggesting that the stock is 5.883% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.291, suggesting its more volatile than the S&P 500 by 29.054%.

Merck KGaA has a quarterly dividend of $0.50 per share corresponding to a yield of 1.94%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck KGaA pays 10.23% of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend. Merck KGaA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck KGaA quarterly revenues are $5.6B, which are larger than InflaRx NV quarterly revenues of -$450. Merck KGaA's net income of $773.4M is higher than InflaRx NV's net income of -$8.7M. Notably, Merck KGaA's price-to-earnings ratio is 18.49x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.45x versus 294.66x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.

Immatics NV has a net margin of 13.92% compared to Merck KGaA's net margin of -214.48%. Merck KGaA's return on equity of 9.69% beat Immatics NV's return on equity of -4.67%.

Merck KGaA has a consensus price target of $35.10, signalling upside risk potential of 36.15%. On the other hand Immatics NV has an analysts' consensus of $14.33 which suggests that it could grow by 134.59%. Given that Immatics NV has higher upside potential than Merck KGaA, analysts believe Immatics NV is more attractive than Merck KGaA.

Merck KGaA has a beta of 0.941, which suggesting that the stock is 5.883% less volatile than S&P 500. In comparison Immatics NV has a beta of 0.811, suggesting its less volatile than the S&P 500 by 18.925%.

Merck KGaA has a quarterly dividend of $0.50 per share corresponding to a yield of 1.94%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck KGaA pays 10.23% of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend. Merck KGaA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck KGaA quarterly revenues are $5.6B, which are larger than Immatics NV quarterly revenues of $19.6M. Merck KGaA's net income of $773.4M is higher than Immatics NV's net income of -$41.9M. Notably, Merck KGaA's price-to-earnings ratio is 18.49x while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.45x versus 4.45x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.